Thromboxane-Prostanoid Receptor Signaling Drives Persistent Fibroblast Activation in Pulmonary Fibrosis.
Toshio Suzuki, Jonathan A Kropski, Jingyuan Chen...
https://pubmed.ncbi.nlm.nih.gov/35728047/Actively Recruiting
Led by Cumberland Pharmaceuticals · Updated on 2026-09-02
128
Participants Needed
20
Research Sites
N/A
Total Duration
Researchers are studying oral ifetroban to evaluate its safety and effectiveness in treating patients with Idiopathic Pulmonary Fibrosis IPF, a lung disease that causes fibrosis from various causes including genetic factors, bleomycin, and radiation. This phase II, multicenter, randomized, placebo-controlled trial compares daily oral ifetroban to a placebo over 12 months. The study aims to assess lung function changes and other important health outcomes in people with IPF. Participants will be randomly assigned to receive either oral ifetroban 250 mg once daily or a matching placebo, with both groups continuing any stable background antifibrotic or pulmonary hypertension therapies. The treatment period lasts for 12 months, during which participants take their assigned capsules daily. Blood and urine samples will be collected to study standard and novel biomarkers related to progressive pulmonary fibrosis. During the trial, participants will undergo safety monitoring and efficacy assessments, including lung function tests measuring forced vital capacity FVC. Researchers will also track acute exacerbations, hospitalizations, quality of life, and adverse events. The study includes regular evaluations throughout the 12-month period to carefully monitor health status and treatment effects, with a focus on maintaining participant safety and adherence.
CONDITIONS
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
I
Ines Macias-Perez, PhD
I
Ingrid Anderson, PhD, CCRP
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cumberland Pharmaceuticals
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Oral Ifetroban sodium once daily | Oral matching placebo | Pirfenidone or Nintedanib (current standard) |
|---|---|---|---|
| What it is | An investigational oral drug being tested once daily for treatment of IPF | A matching oral placebo arm representing no active drug | Approved antifibrotic medications pirfenidone or nintedanib commonly used in IPF care |
| Role in trial | Investigational treatment arm | Randomized comparator arm with no active drug | Current usual antifibrotic care outside the study |
| Use | To test efficacy in slowing FVC decline over 12 months | To serve as control arm for comparison with investigational drug | Used in routine practice to slow disease progression |
| How it is given or performed | Oral once-daily administration | Oral once-daily matching placebo | Oral medications taken according to approved regimens |
| Evidence status | Effectiveness under investigation in this randomized trial | Serves as inactive control arm | Known to slow lung function decline but do not stop disease progression |
| Important risks | Unknown; safety to be established by trial | No drug exposure, minimal safety concerns beyond placebo effects | Associated with tolerability issues and adverse events in real-world use |
| Important limitations | Efficacy and safety are not established until trial completion | Not a therapeutic option; used only for comparison | Do not halt disease progression and may have side effects leading to discontinuation |
| Patient impact | Not yet known; trial will measure lung function and exacerbations | No therapeutic benefit; serves as control comparator | Associated with slower progression and may improve symptom stability, though side effects affect tolerability |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants take either oral ifetroban 250 mg or a matching placebo once daily for 12 months while continuing stable background therapies if applicable.
Regular visits for safety and efficacy assessments throughout treatment
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Toshio Suzuki, Jonathan A Kropski, Jingyuan Chen...
https://pubmed.ncbi.nlm.nih.gov/35728047/Cumberland Pharmaceuticals
Lead Sponsor